Market revenue in 2023 | USD 55.3 million |
Market revenue in 2030 | USD 74.9 million |
Growth rate | 4.4% (CAGR from 2023 to 2030) |
Largest segment | Cystitis |
Fastest growing segment | Pyelonephritis |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Urethritis, Cystitis, Pyelonephritis |
Key market players worldwide | Qiagen NV, Bio-Rad Laboratories Inc, Roche Holding AG, Danaher Corp, Siemens Healthineers AG ADR, Thermo Fisher Scientific Inc, BioMerieux SA, T2 Biosystems Inc, Accelerate Diagnostics Inc, Randox |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to urinary tract infection testing market will help companies and investors design strategic landscapes.
Cystitis was the largest segment with a revenue share of 41.23% in 2023. Horizon Databook has segmented the Latin America urinary tract infection testing market based on urethritis, cystitis, pyelonephritis covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of continent-level data and insights on the Latin America urinary tract infection testing market , including forecasts for subscribers. This continent databook contains high-level insights into Latin America urinary tract infection testing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account